Lonza Group Ltd. Announces the Extension of the Existing Supply Agreement with Bristol-Myers Squibb Company to Produce Until End 2013 ORENCIA®.

Basel, 12.03.2007 – Lonza, the global life sciences company, announces the extension of the existing supply agreement with Bristol-Myers Squibb Company to produce in its Portsmouth, N.H. (USA) facility until the end of 2013 the active pharmaceutical ingredi-ent for ORENCIA® (abatacept), a biologic agent discovered and developed by Bristol-Myers Squibb for the treatment of rheumatoid arthritis. The extension will provide Bristol-Myers Squibb with additional production capacity in support of future sales of ORENCIA®.